Evaluation of Long-acting Cabotegravir Safety and Pharmacokinetics in Pregnant Women in Eastern and Southern Africa: a Secondary Analysis of HPTN 084

Overview

Journal J Int AIDS Soc

Specialty Infectious Diseases

Date 2025 Jan 3

PMID 39748218

Authors

Sinead Delany-Moretlwe

Brett Hanscom

Xu Guo

Clemensia Nkabiito

Patricia Mandima

Patricia Ntege Nahirya

Juliet Mpendo

Muchaneta Bhondai-Mhuri

Nyaradzo Mgodi

Rebecca Berhanu

Jennifer Farrior

Estelle Piwowar-Manning

Susan L Ford

Craig W Hendrix

Alex R Rinehart

James F Rooney

Adeola Adeyeye

Raphael J Landovitz

Myron S Cohen

Mina C Hosseinipour

Mark A Marzinke

Affiliations

Soon will be listed here.

Abstract

Introduction: Long-acting injectable cabotegravir (CAB-LA) for pre-exposure prophylaxis significantly reduced HIV acquisition in HPTN 084. We report on the safety and CAB-LA pharmacokinetics in pregnant women during the blinded period of HPTN 084.

Methods: Participants were randomized 1:1 to either active cabotegravir (CAB) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) placebo or active TDF/FTC plus CAB placebo. Pregnancy testing was performed at each visit; participants with a positive test had study product withheld and were offered open-label TDF/FTC. Pregnancies were confirmed on two tests at least 4 weeks apart. All participants with a positive pregnancy test prior to November 5, 2020 are included in this analysis. Pregnancy incidence, maternal adverse event (AE) incidence, pregnancy outcomes (including composite outcome of spontaneous abortion <20 weeks, intrauterine foetal death or stillbirth ≥20 weeks, premature birth <37 weeks, or small for gestational age) were assessed. The apparent terminal phase half-life (t) of CAB-LA in pregnant women in HPTN 084 was compared to non-pregnant women from the phase 2a HPTN 077 trial. Multivariable models assessed associations with t RESULTS: Fifty-seven pregnancies (30 CAB-LA, 27 TDF/FTC) were confirmed over 3845 person-years [py] (incidence 1.5/100 py, 95% CI 1.1-1.9). CAB-LA group participants had a median 342 days (IQR 192, 497) of CAB-LA exposure prior to pregnancy detection. Grade 2 or higher maternal AE incidence did not differ by study arm (CAB 157, 95% CI 91-271 per 100 py vs. TDF/FTC 217, 95% CI 124-380 per 100 py; p = 0.256). Most pregnancies (81%) resulted in live births (25 CAB-LA, 22 TDF/FTC). Composite poor pregnancy outcomes did not differ significantly by group (CAB 6/30 vs. TDF/FTC 4/27; p = 0.476). No congenital anomalies were observed. The CAB t geometric mean was 52.8 days (95% CI 40.7-68.4) in pregnant women compared to 60.3 days (95% CI 47.7-76.3; p = 0.66) in non-pregnant women; neither pregnancy nor body mass index were significantly associated with t.

Conclusions: CAB-LA concentrations post-cessation of injections were generally well tolerated in pregnant women. The t was comparable between pregnant and non-pregnant women. Ongoing studies will examine the safety and pharmacology of CAB-LA in women who choose to continue CAB-LA through pregnancy and lactation.

References

Saums M, King C, Adams J, Sheth A, Badell M, Young M . Combination Antiretroviral Therapy and Hypertensive Disorders of Pregnancy. Obstet Gynecol. 2019; 134(6):1205-1214. PMC: 7036166. DOI: 10.1097/AOG.0000000000003584. View

Saint-Lary L, Benevent J, Damase-Michel C, Vayssiere C, Leroy V, Sommet A . Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: a systematic review and.... BMC Pregnancy Childbirth. 2023; 23(1):80. PMC: 9885641. DOI: 10.1186/s12884-023-05347-5. View

Lee A, Katz J, Blencowe H, Cousens S, Kozuki N, Vogel J . National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010. Lancet Glob Health. 2014; 1(1):e26-36. PMC: 4221634. DOI: 10.1016/S2214-109X(13)70006-8. View

Venter W, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N . Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised,.... Lancet HIV. 2020; 7(10):e666-e676. DOI: 10.1016/S2352-3018(20)30241-1. View

Heffron R, Mugo N, Hong T, Celum C, Marzinke M, Ngure K . Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention. AIDS. 2018; 32(12):1707-1713. PMC: 6086376. DOI: 10.1097/QAD.0000000000001867. View

Villar J, Ismail L, Victora C, Ohuma E, Bertino E, Altman D . International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. Lancet. 2014; 384(9946):857-68. DOI: 10.1016/S0140-6736(14)60932-6. View

Blair C, Li S, Chau G, Cottle L, Richardson P, Marzinke M . Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077. J Acquir Immune Defic Syndr. 2020; 85(1):93-97. PMC: 7549535. DOI: 10.1097/QAI.0000000000002409. View

Wilcox A, Weinberg C, OConnor J, Baird D, Schlatterer J, Canfield R . Incidence of early loss of pregnancy. N Engl J Med. 1988; 319(4):189-94. DOI: 10.1056/NEJM198807283190401. View

Landovitz R, Li S, Eron Jr J, Grinsztejn B, Dawood H, Liu A . Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020; 7(7):e472-e481. PMC: 7859863. DOI: 10.1016/S2352-3018(20)30106-5. View

10.

van der Wekken-Pas L, Weiss F, Simon-Zuber C, Sebisch R, Wiese C, van Leeuwen E . Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV. Clin Infect Dis. 2024; 79(6):1468-1471. PMC: 11650856. DOI: 10.1093/cid/ciae242. View

11.

Abrams E, Calmy A, Fairlie L, Mahaka I, Chimula L, Flynn P . Approaches to accelerating the study of new antiretrovirals in pregnancy. J Int AIDS Soc. 2022; 25 Suppl 2:e25916. PMC: 9294864. DOI: 10.1002/jia2.25916. View

12.

Goldenberg R, Davis R, Cliver S, Cutter G, Hoffman H, Dubard M . Maternal risk factors and their influence on fetal anthropometric measurements. Am J Obstet Gynecol. 1993; 168(4):1197-203; discussion 1203-5. DOI: 10.1016/0002-9378(93)90369-t. View

13.

Spreen W, Min S, Ford S, Chen S, Lou Y, Bomar M . Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials. 2013; 14(5):192-203. DOI: 10.1310/hct1405-192. View

14.

Waitt C, Orrell C, Walimbwa S, Singh Y, Kintu K, Simmons B . Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLoS Med. 2019; 16(9):e1002895. PMC: 6754125. DOI: 10.1371/journal.pmed.1002895. View

15.

Makanani B, Balkus J, Jiao Y, Noguchi L, Palanee-Phillips T, Mbilizi Y . Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy. J Acquir Immune Defic Syndr. 2018; 79(5):566-572. PMC: 6231990. DOI: 10.1097/QAI.0000000000001861. View

16.

Mugo N, Hong T, Celum C, Donnell D, Bukusi E, John-Stewart G . Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA. 2014; 312(4):362-71. PMC: 4362516. DOI: 10.1001/jama.2014.8735. View

17.

Trezza C, Ford S, Gould E, Lou Y, Huang C, Ritter J . Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women. Br J Clin Pharmacol. 2017; 83(7):1499-1505. PMC: 5465324. DOI: 10.1111/bcp.13236. View

18.

Balkus J, Brown E, Palanee T, Nair G, Gafoor Z, Zhang J . An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women. J Acquir Immune Defic Syndr. 2016; 72(3):333-43. PMC: 4911322. DOI: 10.1097/QAI.0000000000000974. View

19.

Zash R, Makhema J, Shapiro R . Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. N Engl J Med. 2018; 379(10):979-981. PMC: 6550482. DOI: 10.1056/NEJMc1807653. View

20.

Bengtson A, Phillips T, le Roux S, Brittain K, Zerbe A, Madlala H . Does HIV infection modify the relationship between pre-pregnancy body mass index and adverse birth outcomes?. Paediatr Perinat Epidemiol. 2020; 34(6):713-723. DOI: 10.1111/ppe.12688. View